Veradermics opened lower at $146.66, compared with its previous close of $156.56. In the last trading session, the stock traded between $133.92 and $147.54. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 1 year ago in Veradermics is now worth
$ 358.72
Giving a profit of
$ 258.72 (258.72%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-21.14 (-13.50%)
Day High
$147.54
Day Low
$133.92
Day Open
$146.66
Prev Close
$156.56
Volume
22,18,433
1W Return
-0.93%
1M Return
10.75%
3M Return
24.42%
6M Return
25.24%
1Y Return
258.72%
Fundamentals
Market Cap ($ Mn)
-
PE Ratio
-
PB Ratio
5.03
PEG Ratio
-
ROE
-
ROCE
-103.51%
EPS (TTM)
-
Investment Returns
1 Week
-0.93%
1 Month
10.75%
3 Months
24.42%
6 Months
25.24%
9 Months
207.49%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
13Nov
Veradermics to present at Jefferies Global Healthcare Conference
Veradermics management presents at the Jefferies Global Healthcare Conference in London on November 19, 2026. Presentation scheduled for 8:30 am GMT / 3:30 am EST with live webcast available online. Lead asset VDPHL01 is an oral non-hormonal drug in Phase 3 development for pattern hair loss. VDPHL01 uses extended-release technology to minimize cardiac risks and improve efficacy. Patent protection for VDPHL01 extends until 2043.
Today
11Nov
Citigroup raises Veradermics price target to $175, maintains Buy
Citigroup analyst Geoff Meacham raised the price target for Veradermics to $175. The previous price target was set at $160. The firm maintained a Buy rating on the stock.
2 days ago
10Nov
Leerink raises Veradermics price target to $150 after trial data
Leerink Partners maintains Outperform rating on Veradermics. Price target raised to $150 from $135. Action follows positive Phase 2/3 trial results for VDPHL01. Trial showed 43.9 hairs/cm² increase with twice-daily dosing.
3 days ago
19Oct
Veradermics shares jump 10% after VDPHL01 meets all Phase 3 endpoints
Veradermics shares rose 10.11% to $119.82 following positive Phase 3 results. VDPHL01 met all primary and secondary endpoints in Study ‘304’ with p-value <0.0001. Twice-daily dosing showed 36.4 hairs/cm² increase vs 6.6 for placebo at Month 6. Trial enrolled 536 men; no treatment-related serious adverse events were observed. Full dataset supports potential approval as first non-hormonal oral treatment.
24 days ago
19Oct
Needham raises Veradermics price target to $172, maintains Buy rating
Needham maintains a Buy rating on Veradermics. Price target increased from $164 to $172. Analyst Serge Belanger issued the updated guidance.
24 days ago
19Oct
Cantor Fitzgerald reiterates overweight rating on Veradermics
Cantor Fitzgerald reiterated an Overweight rating on Veradermics. Analyst Prakhar Agrawal issued the rating update. No change to the previous Overweight designation was made.
